Dependence receptors and colorectal cancer

Gut

Volumn 63, Issue 11, 2014, Pages 1821-1829

  Mehlen, Patrick ^a   Tauszig Delamasure, Servane ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANDROGEN RECEPTOR; CELL ADHESION ASSOCIATED ONCOGENE REGULATED PROTEIN; DELETED IN COLORECTAL CARCINOMA PROTEIN; DEPENDENCE RECEPTOR; EPHRIN RECEPTOR A4; LIGAND; NEOGENIN; NETRIN 1; NEUROTROPHIN 3 RECEPTOR; ONCOPROTEIN; PLEXIN D1; PROTEIN P75; PROTEIN PATCHED 1; PROTEIN RET; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE A; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; UNCOORDINATED 5A; UNCOORDINATED 5B; UNCOORDINATED 5C; UNCOORDINATED 5D; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR; CELL SURFACE RECEPTOR; NETRIN RECEPTORS; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER GROWTH; CANCER RISK; COLON CARCINOGENESIS; COLORECTAL CANCER; DELETED IN COLORECTAL CARCINOMA GENE; DISEASE PREDISPOSITION; GENE MUTATION; HUMAN; INFLAMMATION; INTRACELLULAR SIGNALING; NETRIN 1 GENE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; TUMOR SUPPRESSOR GENE; ANIMAL; CLASSIFICATION; COLORECTAL TUMOR; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HEDGEHOG PROTEINS; HUMANS; INFLAMMATION; LIGANDS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84907697406     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-306704     Document Type: Article

References (87)

1. Jemal A, Center MM, DeSantis C, et al. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010;19:1893-907.
2. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-3.
3. Clevers H. The intestinal crypt, a prototype stem cell compartment. Cell 2013;154:274-84.
4. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science 2013;339:1546-58.
5. Fearon ER. Molecular genetics of colorectal cancer. Ann Rev Pathol 2011;6:479-507.
6. Vogelstein B, Fearon ER, Kern SE, et al. Allelotype of colorectal carcinomas. Science 1989;244:207-11.
7. Thiagalingam S, Lengauer C, Leach FS, et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996;13:343-6.
8. Fearon ER, Cho K, Nigro J, et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990;247:49-56.
9. Mehlen P, Fearon ER. Role of the dependence receptor DCC in colorectal cancer pathogenesis. J Clin Oncol 2004;22:3420-8.
10. Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994;331:213-21.
11. Lanza G, Matteuzzi M, Gafá R, et al. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 1998;79:390-5.
12. Martinez-Lopez E, Abad A, Font A, et al. Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology 1998;114:1180-7.
13. Ogunbiyi OA, Goodfellow PJ, Herfarth K, et al. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 1998;16:427-33.
14. Barratt PL, Seymour MT, Stenning SP, et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 2002;360:1381-91.
15. Shibata D, Reale MA, Lavin P, et al. The DCC protein and prognosis in colorectal cancer. N Engl J Med 1996;335:1727-32.
16. Sun XF, Rutten S, Zhang H, et al. Expression of the deleted in colorectal cancer gene is related to prognosis in DNA diploid and low proliferative colorectal adenocarcinoma. J Clin Oncol 1999;17:1745-50.
17. Saito M, Yamaguchi A, Goi T, et al. Expression of DCC protein in colorectal tumors and its relationship to tumor progression and metastasis. Oncology 1999;56:134-41.
18. Kato H, Zhou Y, Asanoma K, et al. Suppressed tumorigenicity of human endometrial cancer cells by the restored expression of the DCC gene. Br J Cancer 2000;82:459-66.
19. Fazeli A, Dickinson SL, Hermiston Michelle L, et al. Phenotype of mice lacking functional Deleted in colorectal cancer (Dcc) gene. Nature 1997;386:796-804.
20. Mehlen P, Rabizadeh S, Snipas SJ, et al. The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis. Nature 1998;395:801-4.
21. Mehlen P, Delloye-Bourgeois C, Chedotal A. Novel roles for Slits and netrins: axon guidance cues as anticancer targets? Nat Rev Cancer 2011;11:188-97.
22. Goldschneider D, Mehlen P. Dependence receptors: a new paradigm in cell signaling and cancer therapy. Oncogene 2010;29:1865-82.
23. Mazelin L, Bernet A, Bonod-Bidaud C, et al. Netrin-1 controls colorectal tumorigenesis by regulating apoptosis. Nature 2004;431:80-4.
24. Watson AJ, Pritchard DM. Lessons from genetically engineered animal models. VII. Apoptosis in intestinal epithelium: lessons from transgenic and knockout mice. American journal of physiology. Gastrointest Liver Physiol 2000;278:G1-5.
25. Forcet C, Stein E, Pays L, et al. Netrin-1-mediated axon outgrowth requires deleted in colorectal cancer-dependent MAPK activation. Nature 2002;417:443-7.
26. Castets M, Broutier L, Molin Y, et al. DCC constrains tumour progression via its dependence receptor activity. Nature 2011;482:534-7.
27. Krimpenfort P, Song J-Y, Proost N, et al. Deleted in colorectal carcinoma suppresses metastasis in p53-deficient mammary tumours. Nature 2012;482:538-41.
28. Thiebault K, Mazelin L, Pays L, et al. The netrin-1 receptors UNC5H are putative tumor suppressors controlling cell death commitment. Proc Natl Acad Sci USA 2003;100:4173-8.
29. Llambi F, Causeret F, Bloch-Gallego E, et al. Netrin-1 acts as a survival factor via its receptors UNC5H and DCC. Embo J 2001;20:2715-22.
30. Llambi F, Lourenço FC, Gozuacik D, et al. The dependence receptor UNC5H2 mediates apoptosis through DAP-kinase. Embo J 2005;24:1192-201.
31. Wang H, Ozaki T, Shamim Hossain M, et al. A newly identified dependence receptor UNC5H4 is induced during DNA damage-mediated apoptosis and transcriptional target of tumor suppressor p53. Biochem Biophys Res Commun 2008;370:594-8.
32. Zhu Y, Li Y, Haraguchi S, et al. Dependence receptor UNC5D mediates nerve growth factor depletion-induced neuroblastoma regression. J Clin Invest 2013;123:2935-47.
33. Tanikawa C, Matsuda K, Fukuda S, et al. p53RDL1 regulates p53-dependent apoptosis. Nat Cell Biol 2003;5:216-23.
34. Guenebeaud C, Goldschneider D, Castets M, et al. The dependence receptor UNC5H2/B triggers apoptosis via PP2A-mediated dephosphorylation of DAP kinase. Mol Cell 2010;40:863-76.
35. Bernet A, Mazelin L, Coissieux MM, et al. Inactivation of the UNC5C Netrin-1 receptor is associated with tumor progression in colorectal malignancies. Gastroenterology 2007;133:1840-8.
36. Hibi K, Mizukami H, Shirahata A, et al. Aberrant methylation of the netrin-1 receptor genes UNC5C and DCC detected in advanced colorectal cancer. World J Surg 2009;33:1053-7.
37. Payne SR, Kemp CJ. Tumor suppressor genetics. Carcinogenesis 2005;26:2031-45.
38. Liu P, Lu Y, Liu H, et al. Genome-wide association and fine mapping of genetic loci predisposing to colon carcinogenesis in mice. Mol Cancer Res 2012;10:66-74.
39. Coissieux MM, Tomsic J, Castets M, et al. Variants in the Netrin-1 receptor UNC5C prevent apoptosis and increase risk of familial colorectal cancer. Gastroenterology 2011;141:2039-46.
40. Kury S, Garrec C, Airaud F, et al. Evaluation of the colorectal cancer risk conferred by rare UNC5C alleles. World J Gastroenterol 2014;20:204-13.
41. Paradisi A, Maisse C, Bernet A, et al. NF-kappaB regulates netrin-1 expression and affects the conditional tumor suppressive activity of the netrin-1 receptors. Gastroenterology 2008;135:1248-57.
42. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-96.
43. Paradisi A, Maisse C, Coissieux MM, et al. Netrin-1 up-regulation in inflammatory bowel diseases is required for colorectal cancer progression. Proc Natl Acad Sci USA 2009;106:17146-51.
44. Nielsen CM, Williams J, van den Brink GR, et al. Hh pathway expression in human gut tissues and in inflammatory gut diseases. Lab Invest 2004;84:1631-42.
45. Thibert C, Teillet MA, Lapointe F, et al. Inhibition of neuroepithelial patched-induced apoptosis by sonic hedgehog. Science 2003;301:843-6.
46. Mille F, Thibert C, Fombonne J, et al. The Patched dependence receptor triggers apoptosis through a DRAL-caspase-9 complex. Nat Cell Biol 2009;11:739-46.
47. Fombonne J, Bissey P-A, Guix C, et al. Patched dependence receptor triggers apoptosis through ubiquitination of caspase-9. Proc Natl Acad Sci USA 2012;109:10510-5.
48. Tenzen T, Allen BL, Cole F, et al. The cell surface membrane proteins Cdo and Boc are components and targets of the Hedgehog signaling pathway and feedback network in mice. Dev Cell 2006;10:647-56.
49. Allen BL, Song JY, Izzi L, et al. Overlapping roles and collective requirement for the coreceptors GAS1, CDO, and BOC in SHH pathway function. Dev Cell 2011;20:775-87.
50. Delloye-Bourgeois C, Gibert B, Rama N, et al. Sonic Hedgehog promotes tumor cell survival by inhibiting CDON pro-apoptotic activity. PLoS Biol 2013;11:e1001623.
51. Ingham PW. The patched gene in development and cancer. Curr Opin Genet Dev 1998;8:88-94.
52. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-74.
53. Sahebjam S, Siu LL, Razak AA. The utility of hedgehog signaling pathway inhibition for cancer. The Oncologist 2012;17:1090-9.
54. Kasperczyk H, Baumann B, Debatin KM, et al. Characterization of sonic hedgehog as a novel NF-kappaB target gene that promotes NF-kappaB-mediated apoptosis resistance and tumor growth in vivo. FASEB J 2009;23:21-33.
55. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-65.
56. Bardelli A, Parsons DW, Silliman N, et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003;300:949.
57. Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett 2001;169:107-14.
58. Luo Y, Kaz AM, Kanngurn S, et al. NTRK3 is a potential tumor suppressor gene commonly inactivated by epigenetic mechanisms in colorectal cancer. PLoS Genet 2013;9:e1003552.
59. Segal RA, Goumnerova LC, Kwon YK, et al. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci USA 1994;91:12867-71.
60. Brodeur GM, Nakagawara A, Yamashiro DJ, et al. Expression of TrkA, TrkB and TrkC in human neuroblastomas. J Neurooncol 1997;31:49-55.
61. Tauszig-Delamasure S, Yu LY, Cabrera JR, et al. The TrkC receptor induces apoptosis when the dependence receptor notion meets the neurotrophin paradigm. Proc Natl Acad Sci USA 2007;104:13361-6.
62. Nikoletopoulou V, Lickert H, Frade JM, et al. Neurotrophin receptors TrkA and TrkC cause neuronal death whereas TrkB does not. Nature 2010;467:59-63.
63. Ichim G, Genevois AL, Ménard M, et al. The dependence receptor TrkC triggers mitochondria-dependent apoptosis upon Cobra-1 recruitment. Mol Cell 2013;51:632-46.
64. Genevois AL, Ichim G, Coissieux MM, et al. Dependence receptor TrkC is a putative colon cancer tumor suppressor. Proc Natl Acad Sci USA 2013;110:3017-22.
65. Luo Y, Tsuchiya KD, Il Park D, et al. RET is a potential tumor suppressor gene in colorectal cancer. Oncogene 2013;32:2037-47.
66. Santoro M, Melillo RM, Carlomagno F, et al. Molecular mechanisms of RET activation in human cancer. Ann N Y Acad Sci 2002;963:116-21.
67. Bordeaux MC, Forcet C, Granger L, et al. The RET proto-oncogene induces apoptosis: a novel mechanism for Hirschsprung disease. Embo J 2000;19: 4056-63.
68. Canibano C, Rodriguez NL, Saez C, et al. The dependence receptor Ret induces apoptosis in somatotrophs through a Pit-1/p53 pathway, preventing tumor growth. Embo J 2007;26:2015-28.
69. Draht MX, Smits KM, Tournier B, et al. Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients. Mol Oncol 2014;8:679-88.
70. Foveau B, Leroy C, Ancot F, et al. Amplification of apoptosis through sequential caspase cleavage of the MET tyrosine kinase receptor. Cell Death Differ 2007;14:752-64.
71. Lefebvre J, Muharram G, Leroy C, et al. Caspase-generated fragment of the Met receptor favors apoptosis via the intrinsic pathway independently of its tyrosine kinase activity. Cell Death Dis 2013;4:e871.
72. Samame Perez-Vargas JC, Biondani P, Maggi C, et al. Role of cMET in the development and progression of colorectal cancer. Int J Mol Sci 2013;14:18056-77.
73. Kammula US, Kuntz EJ, Francone TD, et al. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 2007;248:219-28.
74. Levitzki A. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Ann Rev Pharmacol Toxicol 2013;53:161-85.
75. Cohen SJ, Cohen RB, Meropol NJ. Targeting signal transduction pathways in colorectal cancer-more than skin deep. J Clin Oncol 2005;23:5374-85.
76. de Groot JW, Plaza Menacho I, Schepers H, et al. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations. Surgery 2006;139:806-14.
77. Sartore-Bianchi A, Zeppellini A, Amatu A, et al. Regorafenib in metastatic colorectal cancer. Expert Rev Anticancer Ther 2014;14:255-65.
78. Papaetis GS, Syrigos KN. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs 2009;23:377-89.
79. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer 2006;6:449-58.
80. Mittag F, Kuester D, Vieth M, et al. DAPK promotor methylation is an early event in colorectal carcinogenesis. Cancer Lett 2006;240:69-75.
81. Fitamant J, Guenebeaud C, Coissieux MM, et al. Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer. Proc Natl Acad Sci USA 2008;105:4850-5.
82. Delloye-Bourgeois C, Brambilla E, Coissieux MM, et al. Interference with netrin-1 and tumor cell death in non-small cell lung cancer. J Natl Cancer Inst 2009;101:237-47.
83. Delloye-Bourgeois C, Fitamant J, Paradisi A, et al. Netrin-1 acts as a survival factor for aggressive neuroblastoma. J Exp Med 2009;206:833-47.
84. Dumartin L, Quemener C, Laklai H, et al. Netrin-1 mediates early events in pancreatic adenocarcinoma progression, acting on tumor and endothelial cells. Gastroenterology 2010;138:1595-606, 1606 e1591-1598.
85. Bouzas-Rodriguez J, Cabrera JR, Delloye-Bourgeois C, et al. Neurotrophin-3 production promotes human neuroblastoma cell survival by inhibiting TrkC-induced apoptosis. J Clin Invest 2010;120:850-8.
86. Luchino J, Hocine M, Amoureux MC, et al. Semaphorin 3E suppresses tumor cell death triggered by the plexin D1 dependence receptor in metastatic breast cancers. Cancer Cell 2013;24:673-85.
87. Berlin J, Bendell JC, Hart LL, et al. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin Cancer Res 2013;19:258-67.